Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Date:6/23/2011

AMSTERDAM, June 24, 2011 /PRNewswire/ --


 

- Dossier Re-Examination Process Initiated

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera® (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), AMT has been notified that, at this time, Glybera is not approvable.

Subsequent to a review of the CHMP's letter, AMT believes that Glybera can receive a positive opinion subject to generating additional data from existing patients. AMT has therefore decided to ask for a re-examination of the clinical data package.

"From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment. The CHMP also indicated that if certain additional data from already treated patients would confirm current results by the end of 2011, an approval may be possible," noted Jörn Aldag, CEO of AMT. "In the dossier, we provided important data showing Glybera is safe and prevents episodes of pancreatitis, the major clinical complication of LPLD. We appreciate the CHMP's responsibility for caution on such an advanced therapy, so we will work diligently to generate more information and, we hope, ensure that Glybera will still reach patients."

Next steps

As part of the MAA, AMT presented data to the CHMP on Glybera showing evidence in reducing the risk of pancreatitis. Also, the company demonstrated a clear signal of patients' ability to b
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
2. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
3. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
4. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
5. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
6. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
7. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
8. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
9. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
10. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
11. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... -- Kinex Pharmaceuticals announced today that the first patient ... Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, ... inhibitory activity against a broad panel of brain tumor ... (T98G), the most widely used chemotherapy for the treatment ... model, KX2-361 consistently clears brain tumors after 4 weeks ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
...  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... Women,s Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl ... generic equivalent of Teva Women,s Health, Inc.,s  LoSEASONIQUE®. ... of pregnancy.  Terms of the settlement were not ...
... BELLEVUE, Wash., Dec. 7, 2011 Talyst announces ... AutoPharm® Enterprise software. The mobile application can be ... provides greater pharmacy efficiency and control across the ... flexibility for pharmacies to have real-time access to ...
Cached Medicine Technology:Watson Launches Generic LoSEASONIQUE(R) 2Talyst Releases AutoPharm Mobile 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay News) ... write clinical practice guidelines on diabetes and high cholesterol have ... is that compensation by industry on some of these panels ... guideline recommendations," said Dr. Jennifer Neuman, lead author of a ...
... According to a new study in Clinical Gastroenterology ... pain could help physicians know which patients will benefit ... Gastroenterology and Hepatology is the official journal of ... surgeries, or cholecystectomies, are performed annually in the U.S. ...
... , TUESDAY, Oct. 11 (HealthDay News) -- Studies on the ... plagued by design problems, a new report issued by the ... evidence exists that this kind of therapy helps such patients ... to develop definitive guidelines for its use. With traumatic ...
... a regimen once thought to reduce cancer risk ... of a large national study. The finding comes from ... E Cancer Prevention Trial (SELECT). Eric Klein, M.D., chair of ... the lead author. SELECT began in 2001 to test ...
... Reporter , TUESDAY, Oct. 11 (HealthDay News) -- Women who ... both breast and ovarian cancer are more likely to survive ... Those other women include both women with the BRCA1 mutation, ... cancer, and women without either mutation. Researchers ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
Cached Medicine News:Health News:Many on Medical Guideline Panels Have Conflicts of Interest: Study 2Health News:Many on Medical Guideline Panels Have Conflicts of Interest: Study 3Health News:Pain characteristics suggest higher benefit from gallbladder surgery 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 3Health News:National study finds vitamin E supplement may increase prostate cancer risk 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:New project examines medical safety net for undocumented patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: